About Hinova Pharmaceuticals
Hinova Pharmaceuticals is a company based in Lanzhou (China) founded in 2013 by Xinghai Li and Yuanwei Chen.. Hinova Pharmaceuticals has raised $186.63 million across 2 funding rounds from investors including Fosun Pharmaceutical, Tigermed and Aplus Capital. The company has 174 employees as of December 31, 2024. Hinova Pharmaceuticals operates in a competitive market with competitors including Radionetics, Convergent Therapeutics, Nuage Therapeutics, Nymox Pharmaceutical and Glycomantra, among others.
- Headquarter Lanzhou, China
- Employees 174 as on 31 Dec, 2024
- Founders Xinghai Li, Yuanwei Chen
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Hinova Pharmaceuticals, Inc. Class A
-
Annual Revenue
$-6.09 K (USD)0as on Dec 31, 2024
-
Net Profit
$-27.33 M (USD)32.18as on Dec 31, 2024
-
EBITDA
$-30.35 M (USD)32.75as on Dec 31, 2024
-
Total Equity Funding
$186.63 M (USD)
in 2 rounds
-
Latest Funding Round
$146.63 M (USD), Series C
Sep 30, 2020
-
Investors
Fosun Pharmaceutical
& 12 more
-
Employee Count
174
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Hinova Pharmaceuticals
Hinova Pharmaceuticals is a publicly listed company on the SSE with ticker symbol 688302 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Hinova Pharmaceuticals
Hinova Pharmaceuticals has successfully raised a total of $186.63M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $146.63 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series C — $146.6M
-
First Round
First Round
(28 Jul 2019)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Series C - Hinova Pharmaceuticals | Valuation | Rongde Asset Management , CCB International |
|
| Jul, 2019 | Amount | Series B - Hinova Pharmaceuticals | Valuation | Hermed Capital , Fosun Pharmaceutical |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Hinova Pharmaceuticals
Hinova Pharmaceuticals has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Fosun Pharmaceutical, Tigermed and Aplus Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech startups in China are funded by Aplus Capital.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in tech sectors
|
Founded Year | Domain | Location | |
|
DNV Capital is focused on healthcare and smart technology investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hinova Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Hinova Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hinova Pharmaceuticals Comparisons
Competitors of Hinova Pharmaceuticals
Hinova Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Radionetics, Convergent Therapeutics, Nuage Therapeutics, Nymox Pharmaceutical and Glycomantra, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapeutics are developed using dual-targeted radionuclide therapy.
|
|
| domain | founded_year | HQ Location |
Drugs are developed for intrinsically disordered protein targets.
|
|
| domain | founded_year | HQ Location |
Provides research and development of novel drugs and diagnostic products for the aging population
|
|
| domain | founded_year | HQ Location |
Translational glycobiology research on galectin-3 inhibitors is conducted.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hinova Pharmaceuticals
Frequently Asked Questions about Hinova Pharmaceuticals
When was Hinova Pharmaceuticals founded?
Hinova Pharmaceuticals was founded in 2013 and raised its 1st funding round 6 years after it was founded.
Where is Hinova Pharmaceuticals located?
Hinova Pharmaceuticals is headquartered in Lanzhou, China. It is registered at Lanzhou, Gansu, China.
Who is the current CEO of Hinova Pharmaceuticals?
Yuanwei Chen is the current CEO of Hinova Pharmaceuticals. They have also founded this company.
Is Hinova Pharmaceuticals a funded company?
Hinova Pharmaceuticals is a funded company, having raised a total of $186.63M across 2 funding rounds to date. The company's 1st funding round was a Series B of $40M, raised on Jul 28, 2019.
How many employees does Hinova Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Hinova Pharmaceuticals is 174.
What does Hinova Pharmaceuticals do?
Hinova Pharmaceuticals was founded in 2013 and is headquartered in Lanzhou, China. Small molecule-based therapeutics are developed by the company for conditions such as late-stage prostate cancer, hyperuricemia, and gout. The pipeline features HC-1119, which is advanced to phase 3 clinical trials for prostate cancer treatment, and HP501, a uric acid transporter inhibitor in phase 1 trials. Operations center on oncology and metabolic disorder targets within the pharmaceutical sector.
Who are the top competitors of Hinova Pharmaceuticals?
Hinova Pharmaceuticals's top competitors include Radionetics, Nuage Therapeutics and Convergent Therapeutics.
Is Hinova Pharmaceuticals publicly traded?
Yes, Hinova Pharmaceuticals is publicly traded on SSE under the ticker symbol 688302.
Who are Hinova Pharmaceuticals's investors?
Hinova Pharmaceuticals has 13 investors. Key investors include Fosun Pharmaceutical, Tigermed, Aplus Capital, Infinity Group, and Rongde Asset Management.
What is Hinova Pharmaceuticals's ticker symbol?
The ticker symbol of Hinova Pharmaceuticals is 688302 on SSE.